KDR and medullary thyroid gland carcinoma: Vandetanib is the first targeted medication specifically approved by the FDA for the treatment of MTC, acting not only on epidermal growth factor receptor (EGFR), VEGFR, and RET in cancer cells but also inhibiting other TK and serine/threonine kinases and possessing anti-angiogenesis properties.